Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2004 Dec;75(12):1672–1677. doi: 10.1136/jnnp.2003.028761

Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study

R Katzenschlager 1, A Evans 1, A Manson 1, P Patsalos 1, N Ratnaraj 1, H Watt 1, L Timmermann 1, R Van der Giessen 1, A Lees 1
PMCID: PMC1738871  PMID: 15548480

Abstract

Background: The seed powder of the leguminous plant, Mucuna pruriens has long been used in traditional Ayurvedic Indian medicine for diseases including parkinsonism. We have assessed the clinical effects and levodopa (L-dopa) pharmacokinetics following two different doses of mucuna preparation and compared them with standard L-dopa/carbidopa (LD/CD).

Methods: Eight Parkinson's disease patients with a short duration L-dopa response and on period dyskinesias completed a randomised, controlled, double blind crossover trial. Patients were challenged with single doses of 200/50 mg LD/CD, and 15 and 30 g of mucuna preparation in randomised order at weekly intervals. L-Dopa pharmacokinetics were determined, and Unified Parkinson's Disease Rating Scale and tapping speed were obtained at baseline and repeatedly during the 4 h following drug ingestion. Dyskinesias were assessed using modified AIMS and Goetz scales.

Results: Compared with standard LD/CD, the 30 g mucuna preparation led to a considerably faster onset of effect (34.6 v 68.5 min; p = 0.021), reflected in shorter latencies to peak L-dopa plasma concentrations. Mean on time was 21.9% (37 min) longer with 30 g mucuna than with LD/CD (p = 0.021); peak L-dopa plasma concentrations were 110% higher and the area under the plasma concentration v time curve (area under curve) was 165.3% larger (p = 0.012). No significant differences in dyskinesias or tolerability occurred.

Conclusions: The rapid onset of action and longer on time without concomitant increase in dyskinesias on mucuna seed powder formulation suggest that this natural source of L-dopa might possess advantages over conventional L-dopa preparations in the long term management of PD. Assessment of long term efficacy and tolerability in a randomised, controlled study is warranted.

Full Text

The Full Text of this article is available as a PDF (114.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apaydin H., Ertan S., Ozekmekçi S. Broad bean (Vicia faba)--a natural source of L-dopa--prolongs "on" periods in patients with Parkinson's disease who have "on-off" fluctuations. Mov Disord. 2000 Jan;15(1):164–166. doi: 10.1002/1531-8257(200001)15:1<164::aid-mds1028>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  2. Bakke O. M., Scheline R. R. Inhibition of a minor pathway of L-dopa metabolism in the intestinal lumen using a decarboxylase inhibitor (Ro 4-4602). J Pharm Pharmacol. 1974 May;26(5):377–379. doi: 10.1111/j.2042-7158.1974.tb09298.x. [DOI] [PubMed] [Google Scholar]
  3. Bergmark J., Carlsson A., Granerus A. K., Jagenburg R., Magnusson T., Svanborg A. Decarboxylation of orally administered L-dopa in the human digestive tract. Naunyn Schmiedebergs Arch Pharmacol. 1972;272(4):437–440. doi: 10.1007/BF00501249. [DOI] [PubMed] [Google Scholar]
  4. Bermejo Pareja F., Martinez-Martin P., Muradas V., de Yébenes J. G. Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism. Acta Neurol Scand. 1985 Nov;72(5):506–511. doi: 10.1111/j.1600-0404.1985.tb00908.x. [DOI] [PubMed] [Google Scholar]
  5. Bianchine J. R., Messiha F. S., Hsu T. H. Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):584–594. doi: 10.1002/cpt1972134584. [DOI] [PubMed] [Google Scholar]
  6. Birkmayer W. Experimentelle Ergebnisse über die Kombinationsbehandlung des Parkinson-Syndroms mit L-DOPA und einem Decarboxylasehemmer (Ro 4-4602) Wien Klin Wochenschr. 1969 Sep 26;81(39):677–679. [PubMed] [Google Scholar]
  7. Cedarbaum J. M., Kutt H., Dhar A. K., Watkins S., McDowell F. H. Effect of supplemental carbidopa on bioavailability of L-dopa. Clin Neuropharmacol. 1986;9(2):153–159. doi: 10.1097/00002826-198604000-00006. [DOI] [PubMed] [Google Scholar]
  8. Damodaran M., Ramaswamy R. Isolation of l-3:4-dihydroxyphenylalanine from the seeds of Mucuna pruriens. Biochem J. 1937 Dec;31(12):2149–2152. doi: 10.1042/bj0312149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Daxenbichler M. E., VanEtten C. H., Earle F. R., Tallent W. H. -Dopa recovery from Mucuna seed. J Agric Food Chem. 1972 Sep-Oct;20(5):1046–1047. doi: 10.1021/jf60183a002. [DOI] [PubMed] [Google Scholar]
  10. Dujovne C. A., Weiss P., Bianchine J. R. Comparative clinical therapeutic trial with two hypolipidemic drugs: lofibrate and nafenopin. Clin Pharmacol Ther. 1971 Jan-Feb;12(1):117–125. doi: 10.1002/cpt1971121117. [DOI] [PubMed] [Google Scholar]
  11. Dunner D. L., Brodie H. K., Goodwin F. K. Plasma DOPA response to levodopa administration in man: effects of a peripheral decarboxylase inhibitor. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):212–217. doi: 10.1002/cpt1971122part1212. [DOI] [PubMed] [Google Scholar]
  12. Durif F., Vidailhet M., Debilly B., Agid Y. Worsening of levodopa-induced dyskinesias by motor and mental tasks. Mov Disord. 1999 Mar;14(2):242–245. doi: 10.1002/1531-8257(199903)14:2<242::aid-mds1007>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  13. Fahn S. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology. 1974 May;24(5):431–441. doi: 10.1212/wnl.24.5.431. [DOI] [PubMed] [Google Scholar]
  14. Folstein M. F., Folstein S. E., McHugh P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
  15. Gibb W. R., Lees A. J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745–752. doi: 10.1136/jnnp.51.6.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Giovannoni G., van Schalkwyk J., Fritz V. U., Lees A. J. Bradykinesia akinesia inco-ordination test (BRAIN TEST): an objective computerised assessment of upper limb motor function. J Neurol Neurosurg Psychiatry. 1999 Nov;67(5):624–629. doi: 10.1136/jnnp.67.5.624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Goetz C. G., Stebbins G. T., Shale H. M., Lang A. E., Chernik D. A., Chmura T. A., Ahlskog J. E., Dorflinger E. E. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord. 1994 Jul;9(4):390–394. doi: 10.1002/mds.870090403. [DOI] [PubMed] [Google Scholar]
  18. Kaakkola S., Teräväinen H., Ahtila S., Rita H., Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology. 1994 Jan;44(1):77–80. doi: 10.1212/wnl.44.1.77. [DOI] [PubMed] [Google Scholar]
  19. Kurth M. C., Tetrud J. W., Irwin I., Lyness W. H., Langston J. W. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology. 1993 May;43(5):1036–1039. doi: 10.1212/wnl.43.5.1036. [DOI] [PubMed] [Google Scholar]
  20. Manson A. J., Schrag A., Lees A. J. Low-dose olanzapine for levodopa induced dyskinesias. Neurology. 2000 Sep 26;55(6):795–799. doi: 10.1212/wnl.55.6.795. [DOI] [PubMed] [Google Scholar]
  21. Manyam B. V. Paralysis agitans and levodopa in "Ayurveda": ancient Indian medical treatise. Mov Disord. 1990;5(1):47–48. doi: 10.1002/mds.870050112. [DOI] [PubMed] [Google Scholar]
  22. Manyam B. V., Sánchez-Ramos J. R. Traditional and complementary therapies in Parkinson's disease. Adv Neurol. 1999;80:565–574. [PubMed] [Google Scholar]
  23. Mars H. Modification of levodopa effect by systemic decarboxylase inhibition. Arch Neurol. 1973 Feb;28(2):91–95. doi: 10.1001/archneur.1973.00490200039004. [DOI] [PubMed] [Google Scholar]
  24. May P. R., Lee M. A., Bacon R. C. Quantitative assessment of neuroleptic-induced extrapyramidal symptoms: clinical and nonclinical approaches. Clin Neuropharmacol. 1983;6 (Suppl 1):S35–S51. doi: 10.1097/00002826-198300061-00006. [DOI] [PubMed] [Google Scholar]
  25. Merello M., Pikielny R., Cammarota A., Leiguarda R. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study. Clin Neuropharmacol. 1997 Apr;20(2):165–167. doi: 10.1097/00002826-199704000-00008. [DOI] [PubMed] [Google Scholar]
  26. Nagashayana N., Sankarankutty P., Nampoothiri M. R., Mohan P. K., Mohanakumar K. P. Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease. J Neurol Sci. 2000 Jun 15;176(2):124–127. doi: 10.1016/s0022-510x(00)00329-4. [DOI] [PubMed] [Google Scholar]
  27. Nutt J. G. Pharmacodynamics of levodopa in Parkinson's disease. Clin Exp Pharmacol Physiol. 1995 Nov;22(11):837–840. doi: 10.1111/j.1440-1681.1995.tb01946.x. [DOI] [PubMed] [Google Scholar]
  28. Nutt J. G., Woodward W. R., Anderson J. L. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol. 1985 Nov;18(5):537–543. doi: 10.1002/ana.410180505. [DOI] [PubMed] [Google Scholar]
  29. Pappert E. J., Buhrfiend C., Lipton J. W., Carvey P. M., Stebbins G. T., Goetz C. G. Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use. Mov Disord. 1996 Jan;11(1):24–26. doi: 10.1002/mds.870110106. [DOI] [PubMed] [Google Scholar]
  30. Pinder R. M., Brogden R. N., Sawyer P. R., Speight T. M., Avery G. S. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism. Drugs. 1976;11(5):329–377. doi: 10.2165/00003495-197611050-00001. [DOI] [PubMed] [Google Scholar]
  31. Rabey J. M., Vered Y., Shabtai H., Graff E., Korczyn A. D. Improvement of parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption. J Neurol Neurosurg Psychiatry. 1992 Aug;55(8):725–727. doi: 10.1136/jnnp.55.8.725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Reid J. L., Calne D. B., Vakil S. D., Allen J. G., Davies C. A. Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase. J Neurol Sci. 1972 Sep;17(1):45–51. doi: 10.1016/0022-510x(72)90021-4. [DOI] [PubMed] [Google Scholar]
  33. Rinne U. K., Sonninen V., Siirtola T. Plasma concentration of levodopa in patients with Parkinson's disease. Eur Neurol. 1973;10(5):301–310. doi: 10.1159/000114285. [DOI] [PubMed] [Google Scholar]
  34. Shindler J. S., Finnerty G. T., Towlson K., Dolan A. L., Davies C. L., Parkes J. D. Domperidone and levodopa in Parkinson's disease. Br J Clin Pharmacol. 1984 Dec;18(6):959–962. doi: 10.1111/j.1365-2125.1984.tb02571.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Steiger M. J., Stocchi F., Bramante L., Ruggieri S., Quinn N. P. The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease. Clin Neuropharmacol. 1992 Dec;15(6):501–504. doi: 10.1097/00002826-199212000-00007. [DOI] [PubMed] [Google Scholar]
  36. Tripathi Yamini B., Upadhyay Anil K. Effect of the alcohol extract of the seeds of Mucuna pruriens on free radicals and oxidative stress in albino rats. Phytother Res. 2002 Sep;16(6):534–538. doi: 10.1002/ptr.962. [DOI] [PubMed] [Google Scholar]
  37. Yazawa I., Terao Y., Sai I., Hashimoto K., Sakuta M. [Gastric acid secretion and absorption of levodopa in patients with Parkinson's disease--the effect of supplement therapy to gastric acid]. Rinsho Shinkeigaku. 1994 Mar;34(3):264–266. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES